Amnio-Patch™
Contact Us
Akriti Ophthalmic: Advanced Amniotic Membrane Solutions for Eye Care
Transforming ocular surface treatment through innovative regenerative medicine
About Akriti Ophthalmic: Pioneering Eye Care Innovation
Akriti Ophthalmic is dedicated to Simplifying Eye Care, committed to providing safe, affordable, and accessible eye care to all.
Led by Dr. Kuldeep Raizada, the company is headquartered in Hyderabad, India, and focuses on innovative regenerative medicine for advanced eye care solutions.
13M
Life Touched
Providing vision solutions to millions.
1M
Eyes Protected
Ensuring protection for crucial eye health.
1M
Safety Glasses Provided
Promoting eye safety in various settings.
5
Major Projects Completed
Driving significant advancements in eye care.
Akriti Ophthalmic boasts a comprehensive suite of products and a strong commitment to quality, reflected in its extensive certifications and diverse product portfolio.
Certifications & Recognition
  • ISO 9001:2015
  • ISO 13485:2016
  • WHO-GMP
  • CDSCO
  • Startup India Recognition
  • ISO 12870:2016
  • ISO 14889:2013
  • ISO 16034:2002
Product Portfolio
  • Amniotic Membrane Solutions
  • Ophthalmic Implants
  • Eyewear (Safety & Reading Glasses)
  • Diagnostic Tools
With a commitment to zero-defect manufacturing and global accessibility, Akriti Ophthalmic continues to drive innovation in regenerative medicine and advanced eye care solutions, ensuring high-quality products reach patients worldwide.
Leadership Excellence at Akriti Ophthalmic
At the helm of Akriti Ophthalmic is Dr. Kuldeep Raizada, a visionary leader whose dedication has shaped the company's mission to truly Simplify Eye Care. His strategic foresight and unwavering commitment have been instrumental in transforming Akriti Ophthalmic into a pioneering force in advanced eye care solutions.
1
Visionary Founder
Dr. Raizada's journey began with a clear mission: to make safe, affordable, and accessible eye care a reality for all. This foundational vision continues to guide every aspect of Akriti Ophthalmic's operations.
2
Guiding Philosophy
Under Dr. Raizada's leadership, the company thrives on a philosophy centered on innovation, collaboration, and global impact. This approach fuels the development of groundbreaking solutions and fosters strong partnerships.
3
Global Accessibility
His vision extends to ensuring eye care is accessible and affordable across the globe. Dr. Raizada is deeply committed to the fight against preventable blindness and visual impairment, striving for a world where everyone can see clearly.
4
Pioneering Innovation
Dr. Raizada leads the charge in advancing regenerative medicine and ophthalmic innovation. His focus on cutting-edge research and development positions Akriti Ophthalmic at the forefront of the industry.
5
Growth & Excellence
From its beginnings as a Startup India recognized entity, Akriti Ophthalmic has grown significantly under his guidance. Dr. Raizada's emphasis on quality, safety, and patient-centric solutions, backed by extensive international certifications, underpins this success.
Dr. Raizada’s leadership continues to drive Akriti Ophthalmic’s growth, fostering global partnerships and upholding the highest standards of quality, safety, and patient-centricity to ultimately improve eye health outcomes worldwide.
Revolutionising Ocular Healing with Amniotic Membranes
Akriti Ophthalmic stands at the forefront of regenerative eye care, pioneering the use of amniotic membrane technology to address some of the most challenging ocular surface diseases. Our flagship innovations—Amnio-Patch™, Amnio-Disc™, Amnio-ring, Amnio-patch-C, and Natarajan Macuseal—represent decades of research and clinical excellence, bringing hope to patients suffering from conditions that were once considered difficult to treat.
Natural Healing Properties
Harnessing the inherent anti-inflammatory and anti-scarring properties of amniotic tissue to accelerate corneal healing and restore vision naturally
Global Trust
Trusted by ophthalmologists worldwide for treating corneal ulcers, chemical burns, severe dry eye, and post-surgical recovery with proven outcomes
Precision Engineering
Each product is meticulously designed to address specific clinical needs, ensuring optimal therapeutic contact and maximum healing potential
The science behind our products is grounded in the remarkable regenerative capabilities of amniotic membrane tissue. These biological materials contain growth factors, cytokines, and extracellular matrix components that work synergistically to reduce inflammation, prevent fibrosis, and promote epithelialisation. When applied to damaged ocular surfaces, they create an optimal microenvironment for healing, significantly improving patient outcomes compared to conventional therapeutic approaches.
What is Amniotic Membrane Therapy?
Amniotic membrane therapy represents a breakthrough in biological ophthalmology, utilising the innermost layer of the human placenta—the same tissue that protects and nurtures developing babies throughout pregnancy. This remarkable tissue has been used in medicine for over a century, but modern processing and preservation techniques have transformed it into a sophisticated therapeutic tool for eye care.
The amniotic membrane is uniquely positioned in nature to provide optimal healing properties. During pregnancy, it serves as a protective barrier whilst facilitating nutrient transfer and waste removal. These same properties make it ideal for treating damaged ocular surfaces. The membrane contains a rich mixture of growth factors including epidermal growth factor (EGF), transforming growth factor-beta (TGF-β), and basic fibroblast growth factor (bFGF), all of which play crucial roles in tissue repair and regeneration.
What makes amniotic membrane particularly valuable in ophthalmology is its ability to reduce inflammation whilst simultaneously promoting healing. Unlike synthetic materials or traditional bandages, the amniotic membrane actively participates in the healing process. It suppresses the immune response that can lead to scarring, encourages the migration of healthy epithelial cells, and provides a scaffold for new tissue formation. This biological bandage is completely biocompatible, gradually integrating with the patient's own tissue without causing rejection or adverse reactions.

Key Components
  • Growth factors for tissue regeneration
  • Anti-inflammatory cytokines
  • Extracellular matrix proteins
  • Natural antimicrobial peptides
Amnio-Patch™: Precision Healing for Ocular Surfaces
Versatile Application
Designed for easy application across various ocular surface conditions, the Amnio-Patch™ provides comprehensive coverage and protection for damaged corneal and conjunctival tissue
Convenient Storage
Room temperature storage capability with an impressive 5-year shelf life ensures clinical readiness without the need for special freezers or complex handling protocols
Clinical Excellence
Ideal for treating persistent epithelial defects, chemical injuries, neurotrophic keratopathy, and post-surgical wounds with proven healing outcomes
The Amnio-Patch™ represents Akriti Ophthalmic's commitment to making advanced regenerative therapy accessible and practical for everyday clinical use. This innovative product combines the healing power of dehydrated amniotic membrane with a user-friendly design that simplifies application and enhances patient comfort. Unlike cryopreserved alternatives that require complex cold chain logistics, the Amnio-Patch™ can be stored at room temperature, making it immediately available when needed.
Clinical studies have demonstrated the Amnio-Patch™'s effectiveness across a wide spectrum of ocular surface disorders. In cases of persistent epithelial defects—where the corneal surface fails to heal despite conventional treatment—the patch acts as a protective covering whilst delivering growth factors directly to the damaged tissue. For chemical burn victims, where time is critical, the immediate availability of Amnio-Patch™ can mean the difference between vision preservation and permanent damage. The patch's anti-scarring properties are particularly valuable in preventing the formation of symblepharon (adhesions between the eyelid and eyeball) following severe injuries.
Key Features
  • Dehydrated amniotic membrane technology
  • 5-year shelf life at room temperature
  • Sterile, single-use packaging
  • Multiple size options available
  • Easy application protocol
  • Transparent for easy monitoring
Primary Indications
  • Persistent epithelial defects
  • Chemical and thermal burns
  • Neurotrophic keratopathy
  • Post-surgical wound support
  • Recurrent corneal erosions
  • Conjunctival defects
Amnio-Patch™: Advanced Dehydrated Amniotic Membrane Technology
Amnio-Patch™ is Akriti Ophthalmic's advanced solution, representing a significant leap in regenerative ophthalmology. It leverages the inherent healing properties of dehydrated amniotic membrane to provide superior therapeutic outcomes for various ocular surface conditions.
Room Temperature Storage
Amnio-Patch™ can be stored at room temperature, eliminating the need for special freezers and complex cold chain logistics, making it readily available for immediate clinical use.
5-Year Shelf Life
An impressive 5-year shelf life ensures extended usability and reduces waste, contributing to cost-effectiveness and convenient inventory management.
Easy Application
Designed for user-friendliness, Amnio-Patch™ offers a straightforward application protocol, simplifying procedures for ophthalmologists and enhancing patient comfort.
This innovative dehydrated amniotic membrane solution provides significant advantages over cryopreserved alternatives. Its stability at room temperature not only simplifies storage but also ensures that the product is always ready for urgent cases, where time-sensitive intervention can preserve vision. The long shelf life also reduces logistical burdens and potential stock-outs in clinical settings.
Clinical Applications
  • Persistent epithelial defects
  • Chemical and thermal burns
  • Neurotrophic keratopathy
  • Post-surgical wounds
  • Recurrent corneal erosions
  • Conjunctival defects
The professional medical imagery demonstrates the precise application of Amnio-Patch™, showcasing its seamless integration into surgical and clinical procedures. The visual elements emphasize both the convenience and effectiveness of the product in a sterile, professional medical setting.
Amniotic Membrane with Chorion: Advanced Wound Healing Through Regenerative Medicine
Amniotic membrane, derived from the innermost layer of the placenta, along with the chorion, a thicker outer layer, forms a powerful biological dressing in regenerative medicine. These tissues are rich in extracellular matrix components, growth factors, and anti-inflammatory cytokines, making them ideal for promoting tissue regeneration and wound healing. Their unique biological properties contribute to anti-inflammatory, anti-fibrotic, anti-angiogenic, and anti-microbial effects, while also acting as an immune privileged scaffold for cellular migration and proliferation.
Scientific Mechanisms of Wound Healing
The therapeutic efficacy of amniotic membrane with chorion stems from its complex biological composition, which actively modulates all phases of wound healing:
  • Growth Factors: Contains a wide array of growth factors crucial for cell proliferation and tissue repair, including PDGF-AA, PDGF-BB (Platelet-Derived Growth Factors), TGFα, TGFβ1 (Transforming Growth Factors), bFGF (basic Fibroblast Growth Factor), EGF (Epidermal Growth Factor), PLGF (Placental Growth Factor), and GCSF (Granulocyte Colony-Stimulating Factor). These factors stimulate cellular migration, angiogenesis, and collagen synthesis.
  • Interleukins: Possesses immunomodulatory interleukins such as IL-4, IL-6, IL-8, and IL-10. IL-10, in particular, is a potent anti-inflammatory cytokine that helps to resolve inflammation and prevent excessive scarring.
  • Tissue Inhibitors of Metalloproteinases (TIMPs): Contains TIMPs (1, 2, 4) which regulate matrix metalloproteinase activity, thereby preventing excessive degradation of the extracellular matrix and promoting proper tissue remodeling.
Clinical Applications and Evidence
Amniotic membrane with chorion has demonstrated significant clinical success across a diverse range of chronic and acute wounds, often achieving high rates of complete healing:
  • Diabetic Ulcers: Accelerates wound closure and reduces amputation rates.
  • Venous Ulcers: Promotes epithelialization and reduces recurrence.
  • Facial Wounds: Minimizes scarring and improves aesthetic outcomes, as explored in comparative studies (e.g., PMC11089579).
  • Burns: Provides a protective barrier, reduces pain, and facilitates re-epithelialization.
  • Other Chronic Wounds: Effective in non-healing surgical wounds and pressure injuries.
Clinical studies show promising results, with success rates often exceeding 90% for complete healing in chronic wound applications (e.g., PMC11032220, PMC9586828). These outcomes highlight the robust regenerative capacity of this biological tissue.
Comparative Effectiveness of Amnion and Chorion
While both the amniotic membrane and chorion contribute to wound healing, their combined use, particularly in dehydrated human amniotic/chorionic membrane (dHACM) grafts, leverages their synergistic properties. The chorion is thicker and provides additional structural support and a larger reservoir of growth factors and extracellular matrix proteins compared to the amnion alone. This enhanced biological and structural profile contributes to superior clinical performance in challenging wound environments, as detailed in studies on the biological properties of dHACM (e.g., PMC4228928).
Advantages Over Conventional Treatments
Amniotic membrane with chorion offers several advantages compared to traditional wound care approaches:
  • Biological Activity: Actively promotes healing rather than just providing a passive barrier.
  • Reduced Inflammation and Scarring: Its anti-inflammatory and anti-fibrotic properties lead to better functional and aesthetic outcomes.
  • Antimicrobial Properties: Provides a natural defense against infection.
  • Immune Privilege: Low immunogenicity reduces the risk of rejection.
  • Ease of Use: Dehydrated forms offer practical benefits in storage and application.
Future Directions in Research
Ongoing research continues to explore optimized processing techniques, novel delivery methods, and expanded applications for amniotic membrane with chorion. Focus areas include enhanced targeting of specific wound types, combination therapies with other regenerative products, and further elucidation of specific molecular pathways involved in its healing mechanisms. Advances in this field promise even more effective and personalized wound care solutions.
Key Scientific References
  • PMC11089579: Comparative study on facial wound healing.
  • PMC4228928: Biological properties of dehydrated human amniotic/chorionic membrane (dHACM).
  • PMC11032220: Systematic review and meta-analysis of amniotic membrane in wound healing.
  • PMC9586828: Multicenter randomized controlled trial on amniotic membrane for chronic wounds.
Amnio-Disc™: Targeted Corneal Repair in Three Sizes
The Amnio-Disc™ product line advances targeted ocular surface therapy, giving surgeons precise control over treatment delivery. Available in three calibrated sizes (6.00 mm, 8.00 mm, and 10.00 mm), these dehydrated amniotic membrane discs are engineered for optimal placement on corneal lesions of varying dimensions. The disc format offers key advantages over traditional membrane sheets, including standardized sizing for consistent dosing, easier handling, and improved stability upon positioning.
6.00 mm Disc
Precisely sized for smaller corneal lesions and targeted treatment. Ideal for central corneal ulcers, small epithelial defects, and focal limbal stem cell deficiency. This compact size ensures minimal healthy tissue overlap while providing complete coverage of the affected area.
8.00 mm Disc
Designed for larger corneal injuries and extensive surface damage. Perfect for treating peripheral corneal ulcers, post-pterygium excision sites, and broader areas requiring regenerative support. It offers enhanced coverage without compromising the visual axis when properly positioned.
10.00 mm Disc
Provides maximal coverage for extensive defects and reconstructive procedures. Recommended for total limbal stem cell deficiency, large chemical burns, and cases requiring significant epithelial resurfacing. This size ensures comprehensive coverage for diffuse pathology.
Each Amnio-Disc™ undergoes a sophisticated dehydration process, preserving the membrane's biological activity and creating a stable, shelf-ready product. This technique maintains the structural integrity of the extracellular matrix and protects essential growth factors and cytokines for healing. Upon contact with the tear film or surgical irrigation, the disc rapidly rehydrates, conforming to corneal contours and establishing intimate contact with underlying tissue.
Amnio-Disc™ has extensive and well-documented clinical applications. For bacterial or fungal corneal ulcers, the disc provides both mechanical protection and biological support, accelerating healing and minimizing scarring. Following pterygium excision, it covers the bare sclera, significantly reducing recurrence rates compared to bare sclera techniques. In patients with limbal stem cell deficiency, the disc supports re-establishment of a healthy corneal epithelium by providing a scaffold for stem cell migration and differentiation.

Product Specifications
Sizes: 6.00 mm, 8.00 mm, and 10.00 mm diameter
Format: Dehydrated disc
Storage: Room temperature
Shelf Life: 5 years
Packaging: Sterile, single-use
Rehydration: Instantaneous in aqueous environment
Surgical integration of Amnio-Disc™ is remarkably straightforward, with clear protocols for both suture fixation and fibrin glue application. The disc's uniform thickness and consistent quality ensure predictable handling, enabling surgeons to refine placement and fixation techniques. Post-operative monitoring is simplified by its transparency, allowing visualization of the underlying healing process without graft removal or disruption.
Amnio-Patch-C™: Premium Cryopreserved Amniotic Membrane Technology
Amnio-Patch-C represents Akriti Ophthalmic's commitment to innovation, offering a premium cryopreserved amniotic membrane product engineered for complex ocular surface reconstruction. This advanced patch integrates superior features for challenging cases, ensuring optimal healing outcomes.
1
Advanced Composition & Sizing
Amnio-Patch-C is a premium cryopreserved amniotic membrane product with a precise 50 micron thickness. It is available in multiple sizes, ranging from 1cm x 1cm to 10cm x 6cm, allowing for tailored application to various defect sizes.
2
Enhanced Adhesion & Durability
Specifically designed for complex ocular surface reconstruction, Amnio-Patch-C offers superior adhesion and durability. These enhanced properties ensure stable attachment and extended effective treatment periods, even in challenging anatomical locations.
3
Premium Quality & Pricing
The premium pricing of Amnio-Patch-C reflects its advanced processing and enhanced capabilities, making it ideal for cases requiring extensive tissue regeneration where uncompromising quality is paramount.
Amnio-Patch-C provides significant clinical advantages across a range of severe ocular conditions:
Ulcerative Herpetic Keratitis
Supports healing and reduces inflammation in severe herpetic infections.
Corneal Perforations & Descemotoceles
Provides structural support and promotes regeneration in critical corneal defects.
Persistent Corneal Ulcers in Fungal Keratitis
Offers a biological scaffold to aid healing in refractory fungal infections.
Severe Neurotrophic Corneal Ulcers
Enhances re-epithelialization and nerve regeneration in challenging neurotrophic cases.
Infectious Corneal Ulcers & Severe Bacterial Keratitis
Provides a protective barrier and delivers healing factors to combat aggressive infections.
Conjunctival Malignant Melanoma Management
Assists in post-excision reconstruction and reduces recurrence risk.
Pterygium Surgery
Effectively used with suturing or fibrin glue to prevent recurrence and promote smooth ocular surface healing.
Amnio-Patch-C reflects Akriti Ophthalmic's dedication to providing cutting-edge solutions derived from extensive collaboration with leading ophthalmic surgeons. This product addresses critical clinical needs with unparalleled biological efficacy and patient safety.
Amnio-Ring™: Revolutionary Contact Lens-Style Delivery System
The Amnio-ring represents a significant advancement in ocular surface repair, functioning as an innovative contact lens-like carrier system designed to deliver and secure the therapeutic benefits of the amniotic membrane. This breakthrough technology transforms the application of regenerative therapy, making it more efficient and patient-friendly.
Sutureless Application
Eliminates the need for sutures, streamlining the procedure and reducing potential irritation.
Enhanced Patient Comfort
Designed to fit naturally on the eye, significantly improving comfort compared to traditional methods.
Continuous Membrane Contact
Ensures consistent contact between the amniotic membrane and the ocular surface for optimal healing.
The Amnio-ring works through a unique combination of gentle suction and capillary action, which holds the therapeutic amniotic membrane securely in place on the ocular surface without the need for invasive suturing. This mechanism allows for stable and continuous delivery of growth factors and anti-inflammatory agents directly to the damaged tissue.
Easy Insertion & Removal
Designed for simple, non-surgical placement and removal, making the procedure quick and efficient for clinicians.
Reduced Recovery Time
By promoting a stable healing environment, the Amnio-ring contributes to faster and more predictable patient recovery.
Transparent Design for Monitoring
Its clear design allows for easy monitoring of the underlying ocular surface throughout the healing process.
Compared to traditional membrane grafts that often require complex surgical application and can cause discomfort, the Amnio-ring offers a vastly improved patient experience. Its innovative design, emphasizing both ease of use and patient comfort, marks a significant step forward in ocular surface regeneration.
Natarajan MacuSeal™: Revolutionary Dehydrated Amniotic Membrane for Retinal Surgery
Natarajan MacuSeal™, an innovation championed by Dr. Sundaram Natarajan and powered by Akriti Ophthalmic, marks a paradigm shift in retinal surgery. Unlike general ocular surface solutions, MacuSeal™ is specifically engineered as a biologically active, dehydrated amniotic membrane, meticulously sourced from the innermost layer of the placenta. This specialized membrane is designed to address critical needs within the delicate environment of the retina, offering unparalleled support for complex surgical interventions and promoting optimal healing outcomes.
Anti-inflammatory & Anti-fibrotic
Actively reduces inflammation and prevents scar tissue formation, crucial for maintaining retinal function post-surgery.
Promotes Epithelial Healing
Accelerates the regeneration of delicate retinal epithelial cells, supporting faster and more complete recovery.
Immune-Privileged
Minimizes immune response, allowing for seamless integration and reduced risk of rejection in the sensitive ocular environment.
Scaffold for Cellular Processes
Provides a natural biological matrix that encourages cellular migration, proliferation, and differentiation, essential for tissue repair.
Quality Certifications
ISO 10993 Biocompatibility Tested
GMP Certified
CDSCO Approved
ISO 9001 Registered
Primary Clinical Applications
Macular Hole (MH) Closure
Ideal for challenging cases including refractory, large-diameter, or high-myopia-associated macular holes, providing a robust scaffold for closure and regeneration.
Retinal Detachment Repair
Serves as a crucial adjunct in complex retinal detachments, particularly those complicated by Proliferative Vitreoretinopathy (PVR), giant retinal tears, or defects in the posterior pole, enhancing reattachment and reducing recurrence.
Natarajan MacuSeal™ is available in multiple sizes to accommodate diverse surgical needs: 500, 1000, 1500, and 2000 micron diameters. It also offers flexibility in thickness, available in both 50 and 100 micron options, allowing surgeons to select the most appropriate membrane for specific case requirements. The future potential of MacuSeal™ extends into advanced applications, including stem cell enhancement and cutting-edge bioengineering, promising further breakthroughs in retinal care.
Clinical feedback highlights its precision and effectiveness, positioning Natarajan MacuSeal™ as a leading solution for specialized retinal surgery.
Quality and Safety: Akriti's Commitment
At Akriti Ophthalmic, quality and safety are not merely regulatory requirements—they are fundamental principles that guide every aspect of our operations. From donor selection through final product delivery, we maintain rigorous standards that exceed international regulatory requirements. Our commitment to excellence ensures that every amniotic membrane product reaching clinicians and patients represents the highest achievable standards of purity, potency, and safety.
01
Stringent Donor Screening
All tissue donors undergo comprehensive medical history review and serological testing that surpasses FDA and international standards. Only healthy donors undergoing elective caesarean deliveries are considered, with multiple screening checkpoints ensuring tissue integrity and safety.
02
Controlled Collection Protocols
Placental tissue collection follows strict aseptic techniques in accredited surgical facilities. Our trained personnel ensure proper handling from the moment of delivery, maintaining cold chain integrity and documenting every step of the collection process.
03
Advanced Processing Methods
Manufacturing occurs in cGTP-compliant facilities with validated processing procedures. Each batch undergoes multiple quality assessments, including microbiological testing, endotoxin evaluation, and verification of structural integrity throughout processing.
04
Comprehensive Testing Protocols
Final products are subjected to extensive quality control testing, including sterility verification, growth factor activity assays, and physical property assessments. No product is released without complete documentation and approval from our quality assurance team.
05
Secure Packaging and Distribution
Sterile packaging systems maintain product integrity throughout the distribution chain. Our packaging design has been validated to preserve product characteristics across varying environmental conditions whilst ensuring ease of use in clinical settings.
Regulatory Compliance
Akriti Ophthalmic operates under comprehensive regulatory oversight, maintaining registrations and certifications from multiple international regulatory bodies. Our facilities are regularly inspected and our processes continuously audited to ensure ongoing compliance.
  • FDA Current Good Tissue Practice (cGTP) compliance (under processs)
  • ISO 13485 Quality Management System certification
  • Regular third-party audits and inspections
  • Comprehensive traceability systems
  • Adverse event monitoring and reporting
  • Continuous quality improvement programmes
Our quality management system encompasses every stage of product development and manufacturing, from initial research through post-market surveillance. We maintain detailed batch records that provide complete traceability from donor to end user, enabling rapid response should any quality concerns arise. This meticulous documentation also supports our continuous improvement initiatives, allowing us to refine processes based on accumulated data and emerging best practices.
100%
Donor Screening Rate
Every donor undergoes comprehensive medical evaluation and serological testing before tissue acceptance
5
Years Shelf Life
Extended stability ensures product availability when needed without compromise to biological activity
0
Quality Compromises
Unwavering commitment to safety means we never release product that doesn't meet our exacting standards
Beyond regulatory compliance, we invest heavily in ongoing research to better understand the biological mechanisms underlying our products' effectiveness. This research not only enhances our manufacturing processes but also contributes to the broader scientific understanding of amniotic membrane therapy, benefiting the entire ophthalmic community. We regularly publish our findings in peer-reviewed journals and present at international conferences, reinforcing our position as thought leaders in regenerative ophthalmology.
Clinical Impact and Patient Benefits
The true measure of Akriti Ophthalmic's success lies not in technical specifications or regulatory achievements, but in the profound impact our products have on patients' lives. Across thousands of clinical cases worldwide, our amniotic membrane solutions have transformed outcomes for individuals suffering from debilitating ocular surface diseases. From preserving vision in emergency trauma situations to restoring quality of life for chronic dry eye sufferers, the clinical benefits extend far beyond simple wound healing.
75%
Reduction in Inflammation
Clinical studies demonstrate significant decrease in inflammatory markers compared to conventional treatments
60%
Faster Healing Time
Average time to complete epithelialisation reduced substantially versus standard therapeutic approaches
85%
Scar Reduction
Marked decrease in corneal scarring and opacification, preserving visual function and clarity
90%
Patient Satisfaction
Overwhelming majority of patients report improved comfort and quality of life following treatment
One of the most significant advantages of amniotic membrane therapy is its ability to reduce the need for repeat surgical interventions. Traditional treatments for severe ocular surface disease often require multiple procedures, each carrying risks and imposing burdens on patients. By promoting more complete and stable healing, our products frequently enable single-intervention success, dramatically reducing healthcare costs whilst improving patient experience. This is particularly valuable for elderly patients or those with systemic conditions that increase surgical risks.
Clinical Evidence
Extensive peer-reviewed research supports the efficacy of amniotic membrane therapy across diverse conditions:
  • Persistent epithelial defects: 80-95% healing rates within 2-4 weeks
  • Chemical burns: Significant reduction in symblepharon formation
  • Post-pterygium surgery: 70% reduction in recurrence rates
  • Neurotrophic keratopathy: Restored corneal sensation in select cases
  • Limbal stem cell deficiency: Improved epithelial stability and clarity
  • Dry eye disease: Sustained symptom relief and reduced medication dependence
Patient Experience Improvements
Beyond clinical measurements, patients consistently report meaningful quality of life enhancements:
  • Reduced pain and discomfort during healing
  • Decreased dependence on chronic medications
  • Improved visual acuity and clarity
  • Enhanced ability to perform daily activities
  • Reduced fear of vision loss
  • Faster return to work and normal life
The economic benefits of effective amniotic membrane therapy extend beyond individual patients to healthcare systems globally. By reducing the need for prolonged medication regimens, repeat surgeries, and management of complications, these biological treatments offer compelling value propositions. Many healthcare systems have recognised this through favourable reimbursement policies, acknowledging that upfront investment in quality regenerative therapy produces long-term savings through improved outcomes and reduced resource utilisation.
"Akriti's amniotic membrane products have transformed my practice. Cases that would have required months of conservative management now heal in weeks, and my patients are experiencing outcomes I couldn't have imagined a decade ago. The combination of scientific rigour and practical design makes these products indispensable in modern corneal surgery."
— Dr. Rajesh Kumar, Consultant Ophthalmologist, Mumbai
Perhaps most importantly, amniotic membrane therapy offers hope to patients who have exhausted conventional treatment options. For individuals facing potential corneal transplantation or irreversible vision loss, these biological treatments can provide a pathway to preservation or restoration of sight. The psychological impact of avoiding blindness or severe visual impairment cannot be overstated—it represents not just clinical success, but restoration of independence, dignity, and life possibilities.
Discover Akriti Ophthalmic's Amniotic Membrane Solutions Today
We invite you to explore the full potential of regenerative ocular therapy through Akriti Ophthalmic's comprehensive product portfolio. Whether you're an experienced corneal specialist seeking to enhance your therapeutic options or a general ophthalmologist looking to better serve patients with challenging ocular surface conditions, our amniotic membrane solutions offer proven effectiveness backed by rigorous science and unwavering quality commitment.
Comprehensive Product Information
Visit our website at www.akritiophthalmic.com to access detailed technical specifications, clinical study results, surgical technique videos, and case studies demonstrating real-world outcomes across diverse patient populations and clinical scenarios.
Educational Resources
Access our extensive library of educational materials, including peer-reviewed publications, webinar recordings, and step-by-step application guides. Stay current with the latest developments in amniotic membrane therapy through our regularly updated clinical insights section.
Global Community Network
Join thousands of eye care professionals worldwide who are transforming patient outcomes through regenerative ocular therapies. Connect with colleagues, share experiences, and learn from leading experts through our international professional network and regular continuing education programmes.
Personalised Support for Your Practice
Integrating new therapeutic modalities into clinical practice requires more than just product availability—it demands comprehensive support and education. Akriti Ophthalmic is committed to ensuring your success through:
  • One-on-one product training sessions with experienced clinical specialists
  • Customised integration protocols tailored to your practice workflow
  • Ongoing technical support and case consultation services
  • Practice marketing materials to educate your patients
  • Assistance with insurance pre-authorisation and coding
  • Regular updates on clinical advances and product innovations
Take the Next Step in Advanced Ocular Care
Whether you're ready to place your first order or simply want to learn more about how amniotic membrane therapy could benefit your patients, our team is here to assist. We understand that adopting new technologies requires careful consideration, and we're committed to providing all the information and support you need to make informed decisions.
Schedule a Consultation
Speak directly with our clinical specialists to discuss specific cases, explore product selection, and receive personalised recommendations for your practice needs
Request Product Samples
Experience the quality and convenience of our amniotic membrane products firsthand through our clinical evaluation programme for qualified practitioners
Attend a Training Session
Participate in hands-on surgical workshops or virtual training sessions led by expert surgeons with extensive experience in amniotic membrane applications
The future of ocular surface therapy is here, combining nature's regenerative wisdom with modern biomedical engineering. Akriti Ophthalmic stands ready to partner with you in bringing these transformative treatments to the patients who need them most. Together, we can continue advancing the field of regenerative ophthalmology, one healed eye at a time.
Akriti Ophthalmic—Advancing vision through regenerative innovation
Certification & Global Footprint:
Connect with Akriti Ophthalmic
We value your inquiries and are dedicated to providing comprehensive support. Whether you have general questions, need technical assistance, or are interested in partnership opportunities, our team is ready to connect with you. Reach out through any of the channels below, and let's advance ocular care together.
General Inquiries
Need information about our products or services? Our team is available to assist you.
Our Location & Hours
Visit us or send mail to our corporate office.
Akriti Ophthalmic Pvt Ltd
M34, M35, M36, Medical Devices Park
Sultanpur Village, Patancheru Mandal
Hyderabad – 502319, Telangana, India
North America:
Akriti Ophthalmic USA LLC
401 Ryland St, Ste 200a, Reno, NV, 89502, USA
Smart Technology LLC
12325 Lake Shore Blvd Cleveland OH,44108, USA
Business Hours:
Monday - Friday: 9:00 AM - 6:00 PM (IST)
Saturday: 10:00 AM - 2:00 PM (IST)
Sunday: Closed
Quick Links
Explore more about Akriti Ophthalmic and our solutions.
Connect With Us on Social Media
Stay updated with our latest news, events, and insights.
Find Us on the Map
Locate our office in Hyderabad, Telangana, India.